OraSure Technologies Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OraSure Technologies, Inc. on November 7, 2002. The report addresses a significant regulatory milestone for the Company's diagnostic product line.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance.
Material Changes
The primary material event reported is the receipt of U.S. Food and Drug Administration (FDA) approval for the OraQuick(R) Rapid HIV-1 Antibody Test. This approval specifically covers the detection of HIV-1 antibodies in finger-stick whole blood samples.
Outlook and Management Commentary
Management announced the FDA approval via a press release issued on November 7, 2002, which is attached as Exhibit 99. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the context of this regulatory approval.
Key Facts for Investor Verification
- FDA approval date for OraQuick(R) Rapid HIV-1 Antibody Test: November 7, 2002.
- Approved sample type: Finger-stick whole blood.
- Target analyte: HIV-1 antibodies.
- Reference document: Press Release attached as Exhibit 99.